Bicycle Therapeutics Ltd Cash Flow-to-Debt Ratio
Bicycle Therapeutics Ltd cash flow-to-debt ratio. Bicycle Therapeutics Ltd (BCYC) has a Cash Flow-to-Debt Ratio of -0.51x as of June 2026, meaning its operating cash flow of $-49.61 Million could theoretically repay -1% of its total liabilities ($96.32 Million) in one year. See BCYC free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Bicycle Therapeutics Ltd (2016–2025)
Cash flow-to-debt ratio of Bicycle Therapeutics Ltd from 2016 to 2025. Historical debt coverage capacity for Bicycle Therapeutics Ltd across 10 annual periods. Check cash flow reinvestment rate of Bicycle Therapeutics Ltd to assess the company's total reinvestment commitment from operating cash flow.
Bicycle Therapeutics Ltd Cash Flow-to-Debt Ratio by Year (2016–2025)
Bicycle Therapeutics Ltd cash flow-to-debt ratio by year from 2016 to 2025. Year-by-year debt coverage analysis for Bicycle Therapeutics Ltd. For the full cash flow conversion analysis, see Bicycle Therapeutics Ltd operating cash flow efficiency.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -2.32x | $-249.68 Million | $107.62 Million | ▼ -130.7% |
| 2024 | -1.01x | $-164.72 Million | $163.81 Million | ▼ -272.2% |
| 2023 | -0.27x | $-60.63 Million | $224.41 Million | ▲ +56.1% |
| 2022 | -0.62x | $-86.11 Million | $139.83 Million | ▼ -455.9% |
| 2021 | -0.11x | $-14.79 Million | $133.54 Million | ▲ +59.1% |
| 2020 | -0.27x | $-17.79 Million | $65.69 Million | ▲ +83.9% |
| 2019 | -1.68x | $-28.61 Million | $17.00 Million | ▼ -877.7% |
| 2018 | -0.17x | $-26.08 Million | $151.45 Million | ▼ -1374.7% |
| 2017 | -0.01x | $-1.42 Million | $121.19 Million | ▲ +99.6% |
| 2016 | -2.96x | $-11.27 Million | $3.81 Million | — |